Chronic fatigue syndrome: Inflammation, immune function, and neuroendocrine interactions

Current Rheumatology Reports

Volumn 9, Issue 6, 2007, Pages 482-487

  Klimas, Nancy G ^a   Koneru, Anne O'Brien ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; BETA INTERFERON; CYTOKINE; ESTROGEN; FATTY ACID; FOLINIC ACID; VALGANCICLOVIR; ZINC;

BONE MARROW SUPPRESSION; CHRONIC FATIGUE SYNDROME; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; EPSTEIN BARR VIRUS; FATTY ACID BLOOD LEVEL; GENOMICS; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE DEFICIENCY; IMMUNITY; IMMUNOMODULATION; INFLAMMATION; MITOCHONDRION; NATURAL KILLER CELL; NEUROENDOCRINE SYSTEM; PROTEOMICS; REVIEW; T LYMPHOCYTE; VIRUS GENE; VIRUS INFECTION; VIRUS REACTIVATION; ZINC BLOOD LEVEL;

FATIGUE SYNDROME, CHRONIC; GENOMICS; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; IMMUNE SYSTEM DISEASES; IMMUNITY; INFLAMMATION; PITUITARY-ADRENAL SYSTEM; VIRUSES;

EID: 37349018273     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-007-0078-y     Document Type: Review

References (34)

1. Fukada K, Straus S, Hickie I: The chronic fatigue syndrome: A comprehensive approach to its definition and study. Ann Intern Med 1994, 121:953-959.
2. Landay A, Jessop C, Lennette E, Levy J: Chronic fatigue syndrome: Clinical condition associated with immune activation. Lancet 1991, 338:707-712.
3. Plioplys A: Differential diagnosis in medical assessment. In Handbook of Chronic Fatigue Syndrome. Edited by Jason L, Fennel P, Taylor R. Hoboken: John Wiley and Sons; 2003:26-41.
4. Maher KJ, Klimas NG, Fletcher MA: Chronic fatigue syndrome is associated with diminished intracellular perforin. Clin Exp Immunol 2005, 142:505-511. First study to see cytotoxic T-cell defects as severe as natural killer cell defects using intracellular perforin assay.
5. Hickie I, Davenport T, Wakefield D, et al.: Post-infective and chronic fatigue syndromes precipitated by viral pathogens: Prospective cohort study. BMJ 2006, 333:575. Identified the severity of the primary infection as the primary predictor of the course of illness for patients with CFS.
6. Appel S, Chapman J, Shoenfeld Y: Infections and vaccination in chronic fatigue syndrome: Myth or reality. Autoimmunity 2007, 40:48-53.
7. Maes M, Mihaylova I, De Ruyter M: Lower serum zinc in chronic fatigue syndrome (CFS): Relationships to immune dysfunctions and relevance for the oxidative stress status in CFS. J Affect Disord 2006, 90:141-147.
8. Maes M, Mihaylova I, Leunis JC: In chronic fatigue syndrome, the decreased levels of omega-3 poly unsaturated fatty acids are related to lower serum zinc and defects in T cell activation. Neuro Endocrinol Lett 2005, 26:745-751.
9. Maes M, Mihaylova I, Leunis JC: Chronic fatigue syndrome is accompanied by an IgM-related immune response directed against neopitopes formed by oxidative or nitrosative damage to lipids and proteins. Neuro Endocrinol Lett 2006, 27:615-621.
10. Puri BK: Long-chain polyunsaturated fatty acids and the pathophysiology of myalgic encephalomyelitis (chronic fatigue syndrome). J Clin Pathol 2007, 60:122-124.
11. Grans H, Nilsson M, Dahlman-Wright K, Evengard B: Reduced levels of oestrogen receptor B (beta) mRNA in Swedish patients with chronic fatigue syndrome. J Clin Pathol 2007, 60:195-198. Described genomic findings related to sex hormone pathway abnormalities and CFS.
12. Cleare AJ, Beam J, Allain T, et al.: Contrasting neuroendocrine responses in depression and chronic fatigue syndrome. J Affect Disord 1995, 34:283-289.
13. Demitrack MA, Dale JK, Straus SE, et al.: Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J Clin Endocrinol Metab 1991, 73:1224-1234.
14. Ter Wolbeek M, van Doornen LJ, Kavelaars A, et al.: Longitudinal analysis of pro- and anti-inflammatory cytokine production in severely fatigued adolescents. Brain Behav Immun 2007, Epub ahead of print.
15. Berneman ZN, Ablashi DV, Li G, et al.: Human herpesvirus 7 is a T-lymphotropic virus and is related to, but significantly different from, human herpesvirus 6 and human cytomegalovirus. Proc Natl Acad Sci 1992, 89:10552-10556.
16. White PD, Thomas JM, Kangro HO, et al.: Predictions and associations of fatigue syndrome and mood disorders that occur after infectious mononucleosis. Lancet 2001, 358:1946-1954.
17. Chapenko S, Krumina A, Kozireva S, et al.: Activation of human herpesvirus 6 and 7 in patients with chronic fatigue syndrome. J Clin Virol 2006, 37(Suppl 1):S47-51.
18. Petersen I, Thomas JM, Hamilton WT, White PD: Risk and predictors of fatigue after infectious mononucleosis in a large primary care cohort. QJM 2006; 99:49-55. Described the results of a study investigating the risk factors and predictors of the development of fatigue syndrome following an infection with infectious mononucleosis, or EBV. Identified female sex and premorbid mood disorder as risk factors for fatigue.
19. Gow JW, Behan WM, Simpson K, et al.: Studies on enterovirus in patients with chronic fatigue syndrome. Clin Infect Dis 1994, 18(Suppl 1):S126-129.
20. Maes M, Mihaylova I, Leunis JC: Increased serum IgA and IgM against LPS of enterobacteria higher in chronic fatigue syndrome (CFS): Indication for the involvement of gram-negative bacteria in the etiology of CFS and for the presence of an increased gut-intestinal permeability. J Affect Disord 2007, 99:237-240.
21. Chia JK, Chia AY: Chronic fatigue syndrome is associated with chronic enterovirus infection of the stomach. J Clin Pathol 2007, Epub ahead of print. The first study to look at enterovirus in CFS. Researchers found enterovirus viral capsid protein 1, RNA, and noncytopathic viruses in the stomach biopsy specimens in the majority of CFS patients with chronic gastrointestinal complaints.
22. Jerjes WK, Taylor NF, Wood PJ, Cleare AJ: Enhanced feedback sensitivity to prednisolone in chronic fatigue syndrome. Psychoneuroendocrinology 2007 32:192-198. Described alterations in negative feedback control of HPA axis in patients with CFS using dexamethasone suppression test.
23. Rajeevan MS, Smith AK, Dimulescu I, et al.: Glucocorticoid receptor polymorphisms and haplotypes associated with chronic fatigue syndrome. Genes Brain Behav 2007, 6:167-176.
24. Vernon SD, Whistler T, Cameron B, et al.: Preliminary evidence of mitochondrial dysfunction associated with post-infective fatigue after acute infection with Epstein Barr Virus. BMC Infect Dis 2006, 6:15. Described alterations in gene transcripts among patients with postinfective fatigue following acute infection with EBV. Found that the patients who developed the postinfective fatigue syndrome had gene expression profiles that indicated an altered host response during episode of acute mononucleosis when compared with those patients who recovered without event.
25. Klimas NG, Salvato FR, Morgan R, Fletcher MA: Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol 1990, 28:1403-1410.
26. Landay AL, Jessop C, Lennette ET, Levy JA: Chronic fatigue syndrome: clinical condition associated with immune activation. Lancet 1991, 338:707-712.
27. Maher K, Klimas N, Fletcher MA: Immunology. In Handbook of Chronic Fatigue Syndrome. Edited by Jason L, Fennel P, Taylor R. Hoboken: John Wiley and Sons; 2003:124-151.
28. Caligiuri M, Murray C, Buchwald D, et al.: Phenotypic and functional deficiency in natural killer cells in patients with chronic fatigue syndrome. J Immunol 1987, 139:3306-3313.
29. Siegel SD, Antoni MH, Fletcher MA, et al.: Impaired natural immunity, cognitive dysfunction, and physical symptoms in patients with chronic fatigue syndrome: Preliminary evidence for a subgroup? J Psychosom Res 2006, 60:559-566. Identified subgroup by immune activation and cell function to predict symptom cluster and severity.
30. Kerr JR, Hodgetts A, Langford PR, et al.: Current research priorities in chronic fatigue syndrome/myalgic encephalitis: Disease mechanisms, a diagnostic test and specific treatments. J Clin Pathol 2007, 60:113-116. Reviews potential impact of genomics on diagnosis and treatment of CFS.
31. Kogelnik AM, Loomis K, Hoegh-Petersen M, et al.: Use of valganciclovir in patients with elevated antibody titers against Human Herpesvirus-6 (HHV-6) and Epstein-Barr Virus (EBV) who were experiencing central nervous system dysfunction including long-standing fatigue. J Clin Virol 2006, 37 Suppl 1:S33-8. Phase 1 study of valganciclovir in the subgroup of CFS patients with high antibody titers to HHV-6 and/or EBV; phase 2 studies are currently underway with this group.
32. Lerner AM, Beqaj SH, Deeter RG, et al.: A six-month trial of valganciclovir in the Epstein-Barr virus subset of chronic fatigue syndrome: improvement in left ventricular function. Drugs Today (Barc). 2002, 38:549-561. Phase 1 study of valganciclovir suggesting that subgroup responds to viral suppression.
33. Lundell K, Qazi S, Eddy L, Uckun FM: Clinical activity of folinic acid in patients with chronic fatigue syndrome. Arzneimittelforschung 2006, 56:399-404.
34. Vermeulen RC, Scholte HR: Azithromycin in chronic fatigue syndrome (CFS), an analysis of clinical data. J Transl Med 2006, 4:34.